<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epstein-Barr virus (EBV) is present in <z:hpo ids='HP_0000001'>all</z:hpo> cases of endemic Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) but in few European/North American <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLs</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Gene expression arrays of <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> have defined a consensus <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> profile within which <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> are classifiable as "molecular <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>" (mBL) </plain></SENT>
<SENT sid="2" pm="."><plain>Where endemic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLs</z:e> fall relative to this profile remains unclear, since they not only carry EBV but also display one of two different forms of virus latency </plain></SENT>
<SENT sid="3" pm="."><plain>Here, we use early-passage <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines from different <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> subclones from a <z:e sem="disease" ids="C1298180" disease_type="Neoplastic Process" abbrv="">single tumor</z:e>, to compare EBV-negative cells with EBV-positive cells displaying either classical latency I <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> (where EBNA1 is the only EBV antigen expressed from the <z:mp ids='MP_0002169'>wild-type</z:mp> EBV genome) or Wp-restricted latency (where an EBNA2 gene-deleted virus genome broadens antigen expression to include the EBNA3A, -3B, and -3C proteins and BHRF1) </plain></SENT>
<SENT sid="4" pm="."><plain>Expression arrays show that both types of endemic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> fall within the mBL classification </plain></SENT>
<SENT sid="5" pm="."><plain>However, while EBV-negative and latency I <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLs</z:e> show overlapping profiles, Wp-restricted <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLs</z:e> form a distinct subgroup, characterized by a detectable downregulation of the germinal center (GC)-associated marker Bcl6 and upregulation of genes marking early plasmacytoid differentiation, notably IRF4 and BLIMP1 </plain></SENT>
<SENT sid="6" pm="."><plain>Importantly, these same changes can be induced in EBV-negative or latency I <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells by <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> with an EBNA2-knockout virus </plain></SENT>
<SENT sid="7" pm="."><plain>Thus, we infer that the distinct gene profile of Wp-restricted <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLs</z:e> does not reflect differences in the identity of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> progenitor cell per se but differences imposed on a common progenitor by broadened EBV gene expression </plain></SENT>
</text></document>